Immunotherapy with ponezumab for probable cerebral amyloid angiopathy

OBJECTIVE: Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of β‐amyloid fragments leading to cerebrovascular dysfunction and other brain injuries. This phase 2, randomized, double–blind trial in patients with probable CAA assessed the efficacy and safety of ponezumab, a nov...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Clin Transl Neurol
Main Authors: Leurent, Claire, Goodman, James A., Zhang, Yao, He, Ping, Polimeni, Jonathan R., Gurol, Mahmut Edip, Lindsay, Monica, Frattura, Linda, Sohur, Usharbudh Shivraj, Viswanathan, Anand, Bednar, Martin M., Smith, Eric E., Greenberg, Steven M.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2019
Assuntos:
Research Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469253/
https://ncbi.nlm.nih.gov/pubmed/31020004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.761
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares